# Helene Blasco

## List of Publications by Year in descending order



| | | | |
|---|---|---|---|
| 119 papers | 3,523 citations | 126901 33 h-index | 182417 51 g-index |
| 128 all docs | 128 docs citations | 128 times ranked | 5351 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Metabolomics and lipidomics approaches in human tears: A systematic review. Survey of Ophthalmology, 2022, 67, 1229-1243. | 4.0 | 22 |
| 2 | Metabolomic Studies in Inner Ear Pathologies. Metabolites, 2022, 12, 214. | 2.9 | 6 |
| 3 | The Roles of NEDD4 Subfamily of HECT E3 Ubiquitin Ligases in Neurodevelopment and Neurodegeneration. International Journal of Molecular Sciences, 2022, 23, 3882. | 4.1 | 9 |
| 4 | Metabolic Profile and Pathological Alterations in the Muscle of Patients with Early-Stage Amyotrophic Lateral Sclerosis. Biomedicines, 2022, 10, 1307. | 3.2 | 7 |
| 5 | Behavioral, Hormonal, Inflammatory, and Metabolic Effects Associated with FGF21-Pathway Activation in an ALS Mouse Model. Neurotherapeutics, 2021, 18, 297-308. | 4.4 | 5 |
| 6 | Genes containing hexanucleotide repeats resembling C9ORF72 and expressed in the central nervous system are frequent in the human genome. Neurobiology of Aging, 2021, 97, 148.e1-148.e7. | 3.1 | 1 |
| 7 | Effect of familial clustering in the genetic screening of 235 French ALS families. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 479-484. | 1.9 | 7 |
| 8 | Dysregulations of Expression of Genes of the Ubiquitin/SUMO Pathways in an In Vitro Model of Amyotrophic Lateral Sclerosis Combining Oxidative Stress and SOD1 Gene Mutation. International Journal of Molecular Sciences, 2021, 22, 1796. | 4.1 | 10 |
| 9 | Validation of plasma amino acid profile using UHPLC-mass spectrometer (QDa) as a screening method in a metabolic disorders reference centre: Performance and accreditation concerns. Clinical Biochemistry, 2021, 92, 34-45. | 1.9 | 4 |
| 10 | SHR/NCrl rats as a model of ADHD can be discriminated from controls based on their brain, blood, or urine metabolomes. Translational Psychiatry, 2021, 11, 235. | 4.8 | 3 |
| 11 | Some CSF Kynurenine Pathway Intermediates Associated with Disease Evolution in Amyotrophic Lateral Sclerosis. Biomolecules, 2021, 11, 691. | 4.0 | 8 |
| 12 | TDP43 aggregates: the â€˜SchrÃ¶dingerâ€™s catâ€™ in amyotrophic lateral sclerosis. Nature Reviews Neuroscience, 2021, 22, 514-514. | 10.2 | 5 |
| 13 | Optimization of Sample Preparation for Metabolomics Exploration of Urine, Feces, Blood and Saliva in Humans Using Combined NMR and UHPLC-HRMS Platforms. Molecules, 2021, 26, 4111. | 3.8 | 31 |
| 14 | Megaloblastic anemia-related iron overload and erythroid regulators: a case report. Journal of Medical Case Reports, 2021, 15, 463. | 0.8 | 2 |
| 15 | Quality consideration for the validation of urine TMA and TMAO measurement by nuclear magnetic resonance spectroscopy in Fish Odor Syndrome. Analytical Biochemistry, 2021, 630, 114330. | 2.4 | 2 |
| 16 | A role for SUMOylation in the Formation and Cellular Localization of TDP-43 Aggregates in Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2020, 57, 1361-1373. | 4.0 | 20 |
| 17 | TDP-43-Mediated Toxicity in HEK293T Cells: A Fast and Reproducible Protocol To Be Employed in the Search of New Therapeutic Options against Amyotrophic Lateral Sclerosis. Cells, 2020, 9, 68. | 4.1 | 8 |
| 18 | Conditioned Medium from Cells Overexpressing TDP-43 Alters the Metabolome of Recipient Cells. Cells, 2020, 9, 2198. | 4.1 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Clinical performance of four immunoassays for antibodies to SARS-CoV-2, including a prospective analysis for the diagnosis of COVID-19 in a real-life routine care setting. Journal of Clinical Virology, 2020, 132, 104633. | 3.1 | 14 |
| 20 | The specific metabolome profiling of patients infected by SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine metabolism. Scientific Reports, 2020, 10, 16824. | 3.3 | 103 |
| 21 | Acute pathophysiological myocardial changes following intra-cardiac electrical shocks using a proteomic approach in a sheep model. Scientific Reports, 2020, 10, 20252. | 3.3 | 5 |
| 22 | Is There a Role for Vitamin D in Amyotrophic Lateral Sclerosis? A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2020, 11, 697. | 2.4 | 8 |
| 23 | Metabolomics: A Tool to Understand the Impact of Genetic Mutations in Amyotrophic Lateral Sclerosis. Genes, 2020, 11, 537. | 2.4 | 11 |
| 24 | Predicting the microbial cause of community-acquired pneumonia: can physicians or a data-driven method differentiate viral from bacterial pneumonia at patient presentation?. BMC Pulmonary Medicine, 2020, 20, 62. | 2.0 | 12 |
| 25 | Assessment of the glomerular filtration rate (GFR) in kidney transplant recipients using Bayesian estimation of the iohexol clearance. Clinical Chemistry and Laboratory Medicine, 2020, 58, 577-587. | 2.3 | 5 |
| 26 | Understanding and managing metabolic dysfunction in Amyotrophic Lateral Sclerosis. Expert Review of Neurotherapeutics, 2020, 20, 907-919. | 2.8 | 22 |
| 27 | Preoperative Chemerin Level Is Predictive of Inflammatory Status 1ÂYear After Bariatric Surgery. Obesity Surgery, 2020, 30, 3852-3861. | 2.1 | 10 |
| 28 | Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Pharmacotherapy, 2020, 21, 1103-1110. | 1.8 | 14 |
| 29 | AÎ²1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2020, 21, 2911. | 4.1 | 18 |
| 30 | A novel mutation in the cleavage site N291 of TDP-43 protein in a familial case of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 463-466. | 1.7 | 1 |
| 31 | Pneumonia recovery reprograms the alveolar macrophage pool. JCI Insight, 2020, 5, . | 5.0 | 35 |
| 32 | Typical bulbar ALS can be linked to GARS mutation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 275-277. | 1.7 | 7 |
| 33 | Metabo-lipidomics of Fibroblasts and Mitochondrial-Endoplasmic Reticulum Extracts from ALS Patients Shows Alterations in Purine, Pyrimidine, Energetic, and Phospholipid Metabolisms. Molecular Neurobiology, 2019, 56, 5780-5791. | 4.0 | 34 |
| 34 | The Relevancy of Data Regarding the Metabolism of Iron to Our Understanding of Deregulated Mechanisms in ALS; Hypotheses and Pitfalls. Frontiers in Neuroscience, 2019, 12, 1031. | 2.8 | 19 |
| 35 | Raman spectroscopic screening of high and low molecular weight fractions of human serum. Analyst, The, 2019, 144, 4295-4311. | 3.5 | 35 |
| 36 | Plasma creatinine and amyotrophic lateral sclerosis prognosis: a systematic review and meta-analysis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 199-206. | 1.7 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?. Brain, 2019, 142, 1176-1194. | 7.6 | 128 |
| 38 | Ferritin and LDL-cholesterol as biomarkers of fat-free mass loss in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 441-444. | 1.7 | 4 |
| 39 | Analysis of bodily fluids using vibrational spectroscopy: a direct comparison of Raman scattering and infrared absorption techniques for the case of glucose in blood serum. Analyst, The, 2019, 144, 3334-3346. | 3.5 | 31 |
| 40 | A ferroptosisâ€“based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. Scientific Reports, 2019, 9, 2918. | 3.3 | 91 |
| 41 | Relationship between Metabolomics Profile of Perilymph in Cochlear-Implanted Patients and Duration of Hearing Loss. Metabolites, 2019, 9, 262. | 2.9 | 12 |
| 42 | Phenotypic and genotypic studies of ALS cases in ALS-SMA families. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 432-437. | 1.7 | 8 |
| 43 | Post hoc analysis of plasma amino acid profiles: towards a specific pattern in autism spectrum disorder and intellectual disability. Annals of Clinical Biochemistry, 2018, 55, 543-552. | 1.6 | 18 |
| 44 | Primary fibroblasts derived from sporadic amyotrophic lateral sclerosis patients do not show ALS cytological lesions. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 446-456. | 1.7 | 18 |
| 45 | Identification of metabolic pathway disturbances using multimodal metabolomics in autistic disorders in a Middle Eastern population. Journal of Pharmaceutical and Biomedical Analysis, 2018, 152, 57-65. | 2.8 | 49 |
| 46 | The Metabolic Disturbances of Motoneurons Exposed to Glutamate. Molecular Neurobiology, 2018, 55, 7669-7676. | 4.0 | 12 |
| 47 | Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?Â© Caroline Moreau et al. 2018; Published by Mary Ann Liebert, Inc. This Open Access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.. Antioxidants and Redox Signaling, 2018, 29, 742-748. | 5.4 | 86 |
| 48 | Causative Genes in Amyotrophic Lateral Sclerosis and Protein Degradation Pathways: a Link to Neurodegeneration. Molecular Neurobiology, 2018, 55, 6480-6499. | 4.0 | 59 |
| 49 | Mutation in the RRM2 domain of TDP-43 in Amyotrophic Lateral Sclerosis with rapid progression associated with ubiquitin positive aggregates in cultured motor neurons. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 149-151. | 1.7 | 11 |
| 50 | The combination of four analytical methods to explore skeletal muscle metabolomics: Better coverage of metabolic pathways or a marketing argument?. Journal of Pharmaceutical and Biomedical Analysis, 2018, 148, 273-279. | 2.8 | 27 |
| 51 | Metabolomics and Lipidomics Profiling of a Combined Mitochondrial Plus Endoplasmic Reticulum Fraction of Human Fibroblasts: A Robust Tool for Clinical Studies. Journal of Proteome Research, 2018, 17, 745-750. | 3.7 | 19 |
| 52 | Metabolomics Biomarkers: A Strategy Toward Therapeutics Improvement in ALS. Frontiers in Neurology, 2018, 9, 1126. | 2.4 | 34 |
| 53 | In ALS, a mutation could be worth two steps. Revue Neurologique, 2018, 174, 669-670. | 1.5 | 5 |
| 54 | Enabling quantification of protein concentration in human serum biopsies using attenuated total reflectance â€“ Fourier transform infrared (ATR-FTIR) spectroscopy. Vibrational Spectroscopy, 2018, 99, 50-58. | 2.2 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Validation of metabolomics analysis of human perilymph fluid using liquid chromatography-mass spectroscopy. Hearing Research, 2018, 367, 129-136. | 2.0 | 22 |
| 56 | How Can a Ketogenic Diet Improve Motor Function?. Frontiers in Molecular Neuroscience, 2018, 11, 15. | 2.9 | 49 |
| 57 | A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression. PLoS ONE, 2018, 13, e0198116. | 2.5 | 64 |
| 58 | Endogenous metabolites that are substrates of organic anion transporterâ€™s (OATs) predict methotrexate clearance. Pharmacological Research, 2017, 118, 121-132. | 7.1 | 22 |
| 59 | A novel mutation of the C-terminal amino acid of FUS (Y526C) strengthens FUS gene as the most frequent genetic factor in aggressive juvenile ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 298-301. | 1.7 | 21 |
| 60 | Wildtype motoneurons, ALSâ€Linked SOD1 mutation and glutamate profoundly modify astrocyte metabolism and lactate shuttling. Glia, 2017, 65, 592-605. | 4.9 | 62 |
| 61 | Quality of life of patients treated for giant cell arteritis: a case-control study. Clinical Rheumatology, 2017, 36, 2055-2062. | 2.2 | 9 |
| 62 | A decrease in blood cholesterol after gastrostomy could impact survival in ALS. European Journal of Clinical Nutrition, 2017, 71, 1133-1135. | 2.9 | 11 |
| 63 | Genetics of amyotrophic lateral sclerosis. Revue Neurologique, 2017, 173, 254-262. | 1.5 | 52 |
| 64 | Workflow methodology for rat brain metabolome exploration using NMR, LCâ€“MS and GCâ€“MS analytical platforms. Journal of Pharmaceutical and Biomedical Analysis, 2017, 142, 270-278. | 2.8 | 26 |
| 65 | <scp>SOD</scp>1 mutation can mask C9<scp>orf</scp>72 abnormal expansion. European Journal of Neurology, 2017, 24, e24. | 3.3 | 2 |
| 66 | Hyperphenylalaninemia Correlated with Global Decrease of Antioxidant Genes Expression in White Blood Cells of Adult Patients with Phenylketonuria. JIMD Reports, 2017, 37, 73-83. | 1.5 | 6 |
| 67 | Ultra-filtration of human serum for improved quantitative analysis of low molecular weight biomarkers using ATR-IR spectroscopy. Analyst, The, 2017, 142, 1285-1298. | 3.5 | 56 |
| 68 | Liver involvement in urea cycle disorders: a review of the literature. Journal of Inherited Metabolic Disease, 2017, 40, 757-769. | 3.6 | 54 |
| 69 | Inhibition of Î²-Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral Sclerosis. Scientific Reports, 2017, 7, 5235. | 3.3 | 53 |
| 70 | Low IDL-B and high LDL-1 subfraction levels in serum of ALS patients. Journal of the Neurological Sciences, 2017, 380, 124-127. | 0.6 | 27 |
| 71 | Omics to Explore Amyotrophic Lateral Sclerosis Evolution: the Central Role of Arginine and Proline Metabolism. Molecular Neurobiology, 2017, 54, 5361-5374. | 4.0 | 40 |
| 72 | Panel of Oxidative Stress and Inflammatory Biomarkers in ALS: A Pilot Study. Canadian Journal of Neurological Sciences, 2017, 44, 90-95. | 0.5 | 105 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS. Scientific Reports, 2017, 7, 17652. | 3.3 | 110 |
| 74 | An UPLC-MSMS method to measure plasma homocysteine concentration. Annales De Biologie Clinique, 2017, 75, 334-338. | 0.1 | 1 |
| 75 | NSC-34 Motor Neuron-Like Cells Are Unsuitable as Experimental Model for Glutamate-Mediated Excitotoxicity. Frontiers in Cellular Neuroscience, 2016, 10, 118. | 3.7 | 41 |
| 76 | Specific Metabolome Profile of Exhaled Breath Condensate in Patients with Shock and Respiratory Failure: A Pilot Study. Metabolites, 2016, 6, 26. | 2.9 | 13 |
| 77 | Biomarkers in amyotrophic lateral sclerosis: combining metabolomic and clinical parameters to define disease progression. European Journal of Neurology, 2016, 23, 346-353. | 3.3 | 31 |
| 78 | Low specificity of urinary 3-methoxytyramine in screening of dopamine-secreting pheochromocytomas and paragangliomas. Clinical Biochemistry, 2016, 49, 1205-1208. | 1.9 | 9 |
| 79 | Metabolomics in amyotrophic lateral sclerosis: how far can it take us?. European Journal of Neurology, 2016, 23, 447-454. | 3.3 | 36 |
| 80 | Inborn Errors of Metabolism in Elderly Adults. Journal of the American Geriatrics Society, 2016, 64, e57-8. | 2.6 | 2 |
| 81 | Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism. Neurotherapeutics, 2016, 13, 905-917. | 4.4 | 46 |
| 82 | Validation of amino-acids measurement in dried blood spot by FIA-MS/MS for PKU management. Clinical Biochemistry, 2016, 49, 1047-1050. | 1.9 | 5 |
| 83 | Pure cerebellar ataxia linked to large C9orf72 repeat expansion. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 301-303. | 1.7 | 15 |
| 84 | Sex-dependent effects of chromogranin B P413L allelic variant as disease modifier in amyotrophic lateral sclerosis. Human Molecular Genetics, 2016, 25, ddw304. | 2.9 | 15 |
| 85 | A Multiplatform Metabolomics Approach to Characterize Plasma Levels of Phenylalanine and Tyrosine in Phenylketonuria. JIMD Reports, 2016, 32, 69-79. | 1.5 | 18 |
| 86 | Further development of biomarkers in amyotrophic lateral sclerosis. Expert Review of Molecular Diagnostics, 2016, 16, 853-868. | 3.1 | 17 |
| 87 | Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection. Expert Opinion on Pharmacotherapy, 2016, 17, 1669-1682. | 1.8 | 14 |
| 88 | Inhibition of Pathogenic Mutant SOD1 Aggregation in Cultured Motor Neuronal Cells by Prevention of Its SUMOylation on Lysine 75. Neurodegenerative Diseases, 2016, 16, 161-171. | 1.4 | 13 |
| 89 | Disruption of TCA Cycle and Glutamate Metabolism Identified by Metabolomics in an In Vitro Model of Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2016, 53, 6910-6924. | 4.0 | 37 |
| 90 | Liquid chromatographyâ€“high-resolution mass spectrometry-based cell metabolomics: Experimental design, recommendations, and applications. TrAC - Trends in Analytical Chemistry, 2016, 75, 118-128. | 11.4 | 44 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Vitamin D is Not a Protective Factor in <scp>ALS</scp>. CNS Neuroscience and Therapeutics, 2015, 21, 651-656. | 3.9 | 32 |
| 92 | Nutritional assessment of amyotrophic lateral sclerosis in routine practice: Value of weighing and bioelectrical impedance analysis. Muscle and Nerve, 2015, 51, 479-484. | 2.2 | 32 |
| 93 | Biological followâ€up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis. European Journal of Neurology, 2015, 22, 1385-1390. | 3.3 | 30 |
| 94 | Blood Cell Palmitoleate-Palmitate Ratio Is an Independent Prognostic Factor for Amyotrophic Lateral Sclerosis. PLoS ONE, 2015, 10, e0131512. | 2.5 | 40 |
| 95 | A common functional allele of the Nogo receptor gene, reticulon 4 receptor (RTN4R), is associated with sporadic amyotrophic lateral sclerosis in a French population. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 490-496. | 1.7 | 6 |
| 96 | Metabolomics Study of Urine in Autism Spectrum Disorders Using a Multiplatform Analytical Methodology. Journal of Proteome Research, 2015, 14, 5273-5282. | 3.7 | 98 |
| 97 | Analytical methodology for metabolomics study of adherent mammalian cells using NMR, GC-MS and LC-HRMS. Analytical and Bioanalytical Chemistry, 2015, 407, 8861-8872. | 3.7 | 39 |
| 98 | Iron Metabolism Disturbance in a French Cohort of ALS Patients. BioMed Research International, 2014, 2014, 1-6. | 1.9 | 52 |
| 99 | Assessing the Metabolic Effects of Calcineurin Inhibitors in Renal Transplant Recipients by Urine Metabolic Profiling. Transplantation, 2014, 98, 195-201. | 1.0 | 20 |
| 100 | Combined<sup>1</sup>H-NMR and<sup>1</sup>Hâ€“<sup>13</sup>C HSQC-NMR to improve urinary screening in autism spectrum disorders. Analyst, The, 2014, 139, 3460-3468. | 3.5 | 46 |
| 101 | Untargeted <sup>1</sup> H-NMR metabolomics in CSF. Neurology, 2014, 82, 1167-1174. | 1.1 | 42 |
| 102 | A novel SOD1 mutation p.V31A identified with a slowly progressive form of amyotrophic lateral sclerosis. Neurobiology of Aging, 2014, 35, 266.e1-266.e4. | 3.1 | 17 |
| 103 | Metabolomics in Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis: An Untargeted Approach via High-Resolution Mass Spectrometry. Journal of Proteome Research, 2013, 12, 3746-3754. | 3.7 | 77 |
| 104 | Protein SUMOylation, an emerging pathway in amyotrophic lateral sclerosis. International Journal of Neuroscience, 2013, 123, 366-374. | 1.6 | 29 |
| 105 | 1Hâ€“13C NMR-based urine metabolic profiling in autism spectrum disorders. Talanta, 2013, 114, 95-102. | 5.5 | 79 |
| 106 | GC-MS-based urine metabolic profiling of autism spectrum disorders. Analytical and Bioanalytical Chemistry, 2013, 405, 5291-5300. | 3.7 | 109 |
| 107 | Is NMR metabolic profiling of spent embryo culture media useful to assist in vitro human embryo selection?. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2013, 26, 193-202. | 2.0 | 22 |
| 108 | Biological and neuroimaging biomarkers for amyotrophic lateral sclerosis: 2013 and beyond. Neurodegenerative Disease Management, 2013, 3, 427-444. | 2.2 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | A Rare Motor Neuron Deleterious Missense Mutation in theDPYSL3(CRMP4) Gene is Associated with ALS. Human Mutation, 2013, 34, 953-960. | 2.5 | 30 |
| 110 | Routine Determination of <scp>GFR</scp> in Renal Transplant Recipients by <scp>HPLC</scp> Quantification of Plasma Iohexol Concentrations and Comparison With Estimated <scp>GFR</scp>. Journal of Clinical Laboratory Analysis, 2012, 26, 376-383. | 2.1 | 12 |
| 111 | Amyotrophic lateral sclerosis: A hormonal condition?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 585-588. | 2.1 | 57 |
| 112 | Study of the HFE gene common polymorphisms in French patients with sporadic amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2012, 317, 58-61. | 0.6 | 22 |
| 113 | Homozygous SMN2 deletion is a protective factor in the Swedish ALS population. European Journal of Human Genetics, 2012, 20, 588-591. | 2.8 | 21 |
| 114 | Association between divalent metal transport 1 encoding gene (SLC11A2) and disease duration in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2011, 303, 124-127. | 0.6 | 33 |
| 115 | The P413L chromogranin B variation in French patients with sporadic amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 210-214. | 2.1 | 7 |
| 116 | Filter paper saturated by urine sample in metabolic disorders detection by proton magnetic resonance spectroscopy. Analytical and Bioanalytical Chemistry, 2010, 396, 1205-1211. | 3.7 | 9 |
| 117 | 1H-NMR-Based Metabolomic Profiling of CSF in Early Amyotrophic Lateral Sclerosis. PLoS ONE, 2010, 5, e13223. | 2.5 | 120 |
| 118 | Malnutrition at the time of diagnosis is associated with a shorter disease duration in ALS. Journal of the Neurological Sciences, 2010, 297, 36-39. | 0.6 | 80 |
| 119 | TAR DNA-binding protein of 43 kDa (TDP-43) and amyotrophic lateral sclerosis (ALS): a promising therapeutic target. Expert Opinion on Therapeutic Targets, 0, , 1-18. | 3.4 | 1 |